Famciclovir Articles
MORE ON NETIVUDINE WITHDRAWAL
4 April 1994
WELLCOME'S SHARE PRICE WOES
4 April 1994
EUROPEAN STOCK COMMENT
28 March 1994
WELLCOME BOTTOMING OUT; IMPROVEMENT AHEAD
28 February 1994
ROUND-UP OF 1993'S NEW CHEMICAL ENTITIES
31 January 1994
WINNERS AND LOSERS IN GLOBAL PHARMA INDUSTRY
31 January 1994
EUROPEAN STOCK COMMENT
24 January 1994
1ST FAMVIR LAUNCH SPARKS WELLCOME PRICE CUT
24 January 1994
WELLCOME "TOO FOCUSED" FOR INDEPENDENCE
24 January 1994
EUROPEAN STOCK COMMENT
20 December 1993
FAMCICLOVIR APPROVED IN ITS FIRST MARKET
20 December 1993
WORLD MARKET FOR ANTI-INFECTIVES
15 November 1993
ZOVIRAX PERFORMANCE: A WORRY FOR WELLCOME?
8 November 1993
WELLCOME RESULTS AS EXPECTED BUT US SLOWER
1 November 1993
ANTIVIRAL CLASH LOOMS AS ICAAC DATA PRESENTED
25 October 1993
EUROPEAN STOCK COMMENT
25 October 1993
EUROPEAN STOCK COMMENT
11 October 1993
CLINICAL DATA PRESENTED ON FAMCICLOVIR
4 October 1993
EUROPEAN STOCK COMMENT
4 October 1993
ADAPTING TO A CHANGING DRUG IND ENVIRONMENT
20 September 1993
EUROPEAN STOCK COMMENT
6 September 1993
FAMCICLOVIR NEARING MARKET
26 July 1993
FAMICICLOVIR AS EFFECTIVE AS ZOVIRAX
24 May 1993
ADAPTING TO HEALTH CARE REFORM THE SB WAY
17 May 1993
ACICLOVIR VERSUS PENCICLOVIR
10 May 1993
DRUG FIRMS TO WORK TOGETHER ON AIDS R&D
26 April 1993
SMITHKLINE BEECHAM "EXCELLENT PROGRESS"
26 April 1993
LONDON STOCK COMMENT
12 April 1993
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
